Onconetix (NASDAQ:ONCO) and Voyager Therapeutics (NASDAQ:VYGR) Head to Head Analysis

Voyager Therapeutics (NASDAQ:VYGR) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Voyager Therapeutics and Onconetix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1	0	2	1	2.75
Onconetix	1	0	0	0	1.00

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 441.87%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Onconetix.

Insider & Institutional Ownership

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 0.3% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Voyager Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Valuation and Earnings

This table compares Voyager Therapeutics and Onconetix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37 million	4.65	-$119.72 million	($1.80)	-1.69
Onconetix	$810,000.00	3.54	-$14.03 million	$248.12	0.00

Onconetix has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Voyager Therapeutics and Onconetix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Onconetix	-1,575.89%	-91.95%	-53.76%

Summary

Voyager Therapeutics beats Onconetix on 11 of the 15 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.